Published in Medical Letter on the CDC and FDA, August 20th, 2006
Teva's Meloxicam tablet is the AB-rated generic equivalent of Boehringer Ingelheim Pharmaceuticals, Inc.'s Mobic tablets. This product is indicated for the relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis.
Annual brand product sales in the U.S. were approximately $1 billion for the 12 months ended March 2006, based on IMS data.
Teva Pharmaceutical Industries Ltd., headquartered in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.